taranabant
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Smoking
Conditions
Smoking
Trial Timeline
Jan 1, 2005 → Jun 1, 2005
NCT ID
NCT00109135About taranabant
taranabant is a phase 2 stage product being developed by Merck for Smoking. The current trial status is completed. This product is registered under clinical trial identifier NCT00109135. Target conditions include Smoking.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00131430 | Phase 2/3 | Completed |
| NCT00109135 | Phase 2 | Completed |
Competing Products
20 competing products in Smoking